Deciphera’s Vimseltinib Could Benefit From Liver Safety, Prescriber Overlap in TGCT

Positive topline results from the Phase III MOTION trial showed none of the liver toxicity that earned Daiichi Sankyo’s Turalio a boxed warning and REMS in tenosynovial giant cell tumor.

• Source: Shutterstock

Deciphera Pharmaceuticals, Inc.’s Phase III vimseltinib has a potentially smooth path to market in tenosynovial giant cell tumor (TGCT) thanks to a safety profile more benign than a competing drug for the condition already on the market. Decipher should also benefit from marketing to physicians that mostly overlaps with the one that Deciphera targets for its drug for gastrointestinal stromal tumors (GIST).

The Waltham, MA-based company announced 30 October positive topline results from the Phase III MOTION study of vimseltinib as well as updated Phase I/II results from a study of the...

Key Takeaways
  • Vimseltinib showed a positive improvement in objective response rate compared with placebo in the Phase III MOTION trial, but no cholestatic hepatotoxicity.

  • The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By 

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By 

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By 

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

More from R&D

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By 

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By 

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By 

New CEO Renée Aguiar-Lucander is marking her mark.